ADAR1 Capital Management, LLC bought $1.8M of Tenax Therapeutics (TENX)
Executed Aug 20, disclosed Aug 24, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Aug 24), the stock returned +14.1% (delay-adjusted); from the execution session (Aug 20), +2.2%. Derived: entry at the session's open, exit at the close 20 sessions later.
ADAR1 Capital Management, LLC (10% owner) filed 10 Form 4 reports as a reporting entity in the trailing twelve months (10 purchases, 0 sales), most often in Rallybio Corporation (RLYB). Across 9 priced purchase filings, the average 21-session return was +5.2% from execution and +12.8% from disclosure (delay-adjusted; derived). The largest single filing was $2.1M of RLYB (152,005 sh across 2 lots, as filed), executed May 4.
Healthcare · Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→922,849 sh across 3 lots
Exec Oct 19
Filed Oct 21 · 4:49 PM ET TENXPURCHASE Tenax Therapeutics, Inc. $1.6M
900,000 sh × $1.78
Exec Sep 3
Filed Sep 8 · 5:16 PM ET TENXPURCHASE Tenax Therapeutics, Inc. $1.4M
770,333 sh across 3 lots
Exec Aug 31
Filed Sep 2 · 5:52 PM ET